1 The EIC Accelerator Project
EIC Accelerator Program Overview
The European Innovation Council (EIC) Accelerator program is a cornerstone of the European Union's initiative to foster innovation and support startups and small to medium-sized enterprises (SMEs) in scaling their groundbreaking technologies. The program is designed specifically for DeepTech and high-impact innovations that have the potential to disrupt existing markets or create entirely new ones.
Funding Structure
The EIC Accelerator provides a unique funding structure known as blended finance, which combines grants and equity investments to support the development and commercialization of innovative projects.
Purpose and Impact
The primary goal of the EIC Accelerator is to bridge the funding gap that exists for innovative companies, particularly in the DeepTech sector. Many startups struggle to secure sufficient financing from traditional venture capitalists or banks due to the high-risk nature of their projects. The EIC Accelerator aims to mitigate this risk by providing substantial funding and support, making it easier for startups to attract additional investment from private sources.
The program also plays a vital role in enhancing the European innovation ecosystem by fostering collaboration among various stakeholders, including researchers, industry leaders, and venture capitalists. By supporting startups like SentryX B.V., the EIC Accelerator contributes to the creation of competitive, innovative solutions that can enhance the quality of life and drive economic growth across Europe.
Case Study: SentryX B.V. and the OPERAS Project
SentryX B.V., a company based in the Netherlands, is a proud recipient of the EIC Accelerator funding. The company has developed a project titled OPERAS (Opioid-free Pain relief for Enhanced Recovery After Spine fixation surgery).
Project Overview
The OPERAS project is focused on addressing the significant challenges associated with postoperative pain management, particularly after spine fixation surgery. Traditional pain management methods often rely on opioids, which can lead to various complications, including addiction and adverse side effects. SentryX aims to provide a safer, opioid-free alternative that promotes enhanced recovery for patients.
Technology Basics and Background
The underlying technology of the OPERAS project revolves around innovative pain relief mechanisms that do not involve opioid medications. While specific technical details may be proprietary, the project likely incorporates advanced approaches such as neuromodulation, localized drug delivery, or novel analgesic compounds that target pain receptors more effectively without the associated risks of opioids.
The development of this technology is grounded in extensive research into pain mechanisms and the body's response to surgical interventions. By leveraging insights from both clinical research and patient feedback, SentryX aims to create a solution that not only alleviates pain but also accelerates the recovery process, thereby improving patient outcomes and overall healthcare efficiency.
In summary, the EIC Accelerator program plays a crucial role in supporting innovative companies like SentryX B.V. by providing essential funding and resources needed for the development of transformative technologies. The OPERAS project exemplifies the potential for breakthrough solutions in healthcare, aligning with the program's mission to foster innovation that can significantly impact society.
2 The Funding Rounds
SentryX B.V. (Netherlands): Financing and Funding Overview Since EIC Accelerator Award
EIC Accelerator Funding Award
SentryX B.V., a Dutch clinical-stage biopharmaceutical company specializing in non-opioid pain therapies after surgery, was awarded €15.5 million by the European Innovation Council (EIC) Accelerator in April 2023. This significant funding is aimed at accelerating the clinical development of their lead program, BR-003, an innovative long-acting co-implantable anesthetic designed for spinal fusion surgery and other musculoskeletal procedures.
Financing Raised and Funding Rounds
Seed Round
- Date: June 2021
- Amount: €3.2 million
- Purpose: Development of SentryX’s next-generation pain relief therapeutic platform.
- Lead Investor: Utrecht Health Seed Fund
- Additional Investors/Participants: Not explicitly listed; however, the round included support from investors aligned with healthcare innovation.
EIC Accelerator Grant
- Date Announced: April 2023
- Amount: €15.5 million (grant plus potential equity)
- Reports suggest there may be a mix of grant and equity components in EIC funding rounds; specific breakdown not disclosed publicly.
- Publicly available summaries also reference an amount of €2.5 million from EIC sources but official company channels confirm the larger figure as total secured.
- Use of Funds: To accelerate clinical development—specifically for initiating first-in-human trials with BR-003.
No information is available regarding Series A/B/C rounds or any subsequent private venture financing raised beyond these two main events.
Summary Table
| Round | Date | Amount | Lead Investor / Source | Purpose |
|---|---|---|---|---|
| Seed | Jun 2021 | €3.2M | Utrecht Health Seed Fund | R&D for pain relief therapy platform |
| EIC Accelerator | Apr 2023 | €15.5M | European Innovation Council (EU) | Clinical dev., trials for BR‑003 |
Timing & Details
The seed round closed on June 9, 2021. The EIC Accelerator award was announced in April 2023 following SentryX's successful application through Step 2 submission on January 11, 2023.
Investor Information
Investors identified to date:
Additional references mention discussions with large MedTech companies, VCs, and family offices for future strategic partnerships or commercialization opportunities but do not list further investors as participating in closed rounds since January 11, 2023.
Company Valuations
There are no public disclosures regarding formal company valuations associated with either funding event or subsequent market assessments.
Exit Events (IPO/Buyout/Acquisition)
As of May 2, 2025:
SentryX B.V. has not undergone an IPO nor been acquired or merged into another entity based on all available records since receiving its EIC Accelerator award.
Discussions have been initiated with large MedTech companies about commercial partnerships related to the core product pipeline (“Bupi-Ring”/BR‑003), including possible scenarios involving exclusive deals or distribution agreements—however no exit events have occurred to date.
Sources
SentryX closes €3.2M seed funding round April 2023 - SentryX Awarded €15.5M in EIC Accelerator Funding SentryX company information & investors Opioid-free Pain relief project reporting – CORDIS EU Nieuwsbericht — Health~Holland3 The Press Releases
SentryX B.V.: Innovations and Milestones Post-EIC Accelerator Funding SentryX B.V., a Netherlands-based clinical-stage biopharmaceutical company, secured EIC Accelerator funding through the January 11, 2023, cut-off under the "OPERAS" project. The proposal focused on delivering opioid-free pain relief for enhanced recovery after spinal fixation surgery using their BR-003 hydrogel technology, which administers localized non-opioid analgesics.Technology Advancements and Clinical Progress
- BR-003 Hydrogel Platform: A biocompatible ring co-implanted with spinal screws to deliver targeted pain relief post-surgery. The hydrogel design ensures controlled drug release while minimizing systemic opioid-related side effects.
- Phase 1 Clinical Trials: Initiated in May 2023 across sites in Switzerland and the Netherlands, with the first patient treated in June 2023. A second cohort began enrollment in September 2023.
- Packaging Development: Collaborated with Spark Design to create sterile packaging that doubles as an applicator for precise hydrogel placement during surgery.
Team and Strategic Updates
- Leadership: Co-founders Dr. Jorrit-Jan Verlaan (CMO) and Bas Oosterman (CEO) lead a multidisciplinary team specializing in clinical, regulatory, and technical domains.
- Advisory Board Expansion: Alex Vaccaro (renowned orthopedic surgeon) joined as a strategic advisor in October 2022 to guide clinical development.
Patents and Funding History
- U.S. Patent Approval: First patent granted in March 2023 for their localized drug-delivery platform.
- Seed Funding: Raised €3.2M in June 2021 from Utrecht Health Seed Fund to advance preclinical studies.
Sources
SentryX Awarded €15.5M EIC Accelerator Funding · EIC Accelerator January Cut-off Winners · BR-003 Packaging Collaboration · Company Background · Seed Round Announcement
4 The Technology Advancements
Current Capabilities and Advancements of SentryX B.V.
SentryX B.V., based in the Netherlands, is a clinical-stage biopharmaceutical company focused on developing innovative solutions for acute post-surgical pain, particularly in spine fixation surgery. Their mission is to reduce opioid use and improve recovery outcomes by leveraging a unique implantable hydrogel technology.
Current Capabilities
- Technology: SentryX's lead product, BR-003, is an implantable, biodegradable hydrogel designed to release a powerful local anesthetic, bupivacaine, for over 72 hours. This hydrogel is co-implanted with pedicle screws used in spinal surgery, ensuring seamless integration with existing surgical workflows without altering the procedure.
- Platform Potential: Initially tailored for spine surgery, the technology has potential applications in other musculoskeletal procedures such as joint replacements and fracture fixation.
Advancements Since EIC Accelerator Funding
Since receiving the EIC Accelerator funding in early 2023, SentryX has made significant advancements:
- Clinical Development: The funding has accelerated the clinical development of BR-003, with the goal of expanding its application beyond spinal fusion surgery.
- Team Expansion: SentryX has continued to enhance its team capabilities by hiring experienced professionals in critical areas such as Chemical, Manufacturing, and Controls (CMC).
- Clinical Trials: In June 2023, SentryX achieved a milestone by treating the first patient in a clinical trial. The company has also progressed with initiating sites for Phase 1 clinical trials.
- Recognition: SentryX was selected as a finalist in the AAOS OrthoPitch Competition in December 2024, highlighting its innovative approach to pain management.
Technological Improvements and Demonstrations
- Technological Enhancements: There is no specific mention of new technological features since the funding, but the company's hydrogel technology remains a key innovation, offering controlled drug delivery and biocompatibility.
- Market Demonstrations: While there are no detailed reports on commercial deployments, SentryX's participation in prestigious conferences and competitions indicates its growing presence in the medical technology sector.
Patents and Publications
- Patents: In March 2023, SentryX announced that its first patent was officially granted in the United States, marking a significant milestone in protecting its intellectual property.
- Publications and Clinical Trials: The company has published research on its hydrogel technology, but specific new studies or whitepapers since January 2023 are not noted in the available literature.
Sources
- News - SentryX
- SentryX: Homepage
- SentryX: Implantable Anesthetic for Spine Surgery
- 2025 OrthoPitch Finalists Set to Compete in Showdown at AAOS Meeting
- April 2023 - SentryX Awarded €15.5M in EIC Accelerator Funding
- Technology - SentryX
5 The Partnerships and Customers
SentryX B.V.: Innovative Pain Relief Solutions
SentryX B.V., a life sciences company based in the Netherlands, has been at the forefront of developing next-generation pain relief therapeutics, particularly in the area of post-operative pain management. Following its successful funding from the European Innovation Council (EIC) Accelerator in January 2023, the company has continued to advance its innovative solutions.
Partnerships and Customers
SentryX collaborates with various entities to develop and enhance its pain relief therapies. One notable partnership is with Spark Design, which is involved in designing the sterile packaging and applicator for SentryX’s BR-003 implantable anesthetic ring. This collaboration is crucial for the safe and effective delivery of localized pain treatment after spinal surgery.
Additionally, SentryX has received support from the Utrecht Health Seed Fund (UHSF), which provided seed funding to further develop its pain relief platform. This investment underscores the potential of SentryX’s technology to make a significant impact in orthopedic surgical pain management.
New Partners and Customers
While specific new partners or customers have not been detailed in recent reports, SentryX's ongoing developments and clinical trials suggest a growing network of medical and technological collaborators. The company's participation in prestigious surgical conferences and its progress in clinical trials indicate an expanding presence within the medical community.
Nature of New Relationships and Purpose
SentryX's new relationships are primarily aimed at advancing its BR-003 technology and ensuring its successful integration into clinical settings. The partnerships are designed to enhance the design and delivery of the BR-003 implantable anesthetic, which focuses on providing localized, non-opioid pain relief for patients undergoing spinal surgery.
Market Positioning
The new relationships will position SentryX B.V. as a leader in innovative pain management solutions. By leveraging collaborations with design and clinical partners, SentryX is poised to strengthen its market presence and influence the future of post-operative pain relief.
Technology Advancements and Scaling
These partnerships and investments are crucial for SentryX’s technology advancements and scaling efforts. Collaborations with design and clinical experts enable the refinement of the BR-003 technology, ensuring it meets the highest standards of safety and efficacy. Additionally, the financial support from entities like the EIC Accelerator and UHSF allows SentryX to scale its operations and accelerate its path to market, potentially reducing the reliance on opioid-based pain treatments and improving patient outcomes.
Sources
6 The Hiring and Company Growth
SentryX B.V.: Team Growth and Strategic Expansion Post-EIC Accelerator FundingSentryX B.V., a Netherlands-based innovator in non-opioid pain management solutions, has demonstrated significant team growth and strategic hiring since securing €15.5M in EIC Accelerator funding in April 2023. While exact headcount figures remain undisclosed, the company’s recruitment efforts focus on scaling clinical operations, manufacturing, and leadership capabilities:
- Key Hires:
- June 2024: Two seasoned professionals joined to strengthen Chemical, Manufacturing, and Controls (CMC) capabilities, critical for advancing therapeutic production.
- December 2023: Anne Hoogstraten became Chief People Officer to oversee organizational development, signaling a focus on structured growth.
- January 2024: Hans Schikan (former CEO of ProQR Therapeutics) joined as an informal advisor, enhancing strategic guidance.
- Growth Trajectory:
No major changes in the founding team have been reported since late-2022 updates about JJ Verlaan’s role as CMO/co-founder. Current job postings are not explicitly listed on the SentryX website, but ongoing expansion suggests active recruitment across technical and operational roles.
Sources
7 The Media Features and Publications
SentryX B.V.: Media Presence and Public Engagement Following EIC Accelerator FundingSentryX B.V., a Netherlands-based biotech company developing next-generation pain relief therapeutics, has maintained consistent media visibility and academic engagement since securing €15.5M in EIC Accelerator funding in April 2023. Below is an overview of their public-facing activities, research contributions, and event participation:
Media Features
- RTL Nieuws Feature (July 2024): Highlighted the company’s progress in reducing opioid dependency through its hydrogel-based drug-delivery platform.
- Spark Design Collaboration (May 2023): Partnered to design sterile packaging for their BR-003 implantable anesthetic, emphasizing patient safety and surgical workflow efficiency.
- EIC Soft-Landing Program Recognition (April–May 2024): Featured for participation in the European Innovation Council’s U.S. market-entry initiative for health tech startups.
Publications Citing SentryX
- Acta Biomaterialia (2022): Published findings on gelatin hydrogels for sustained bupivacaine release post-spinal surgery.
- Frontiers in Pain Research (2022): Compared toxicity profiles of bupivacaine formulations in preclinical models.
- Journal of Experimental Orthopaedics (2023): Demonstrated safety of high-concentration bupivacaine in rodent surgical models.
Conference Participation & Events
- AAOS OrthoPitch Competition Finalist (December 2024): Pitched BR-003’s clinical potential at a major orthopedic surgery forum.
- Global Surgical Conferences (June 2023): Attended two unnamed conferences to showcase early clinical trial results from their First-in-Human study.
- EIC USA Soft-Landing Program Workshops: Engaged with U.S. healthcare stakeholders during mentorship sessions in April–May 2024.
Academic Collaborations & Disclosures
Multiple peer-reviewed studies acknowledge SentryX founders’ involvement: Co-founder Prof. J.J. Verlaan is frequently cited as a stakeholder or inventor across spinal surgery-related research, including fluoroscopy-guided navigation algorithms tested on cadavers (PMC9468112*).Podcasts or Interviews
No direct references to podcasts or interviews were identified within available sources; however, CEO Bas Oosterman has publicly commented on investor support and clinical outcomes during funding announcements (UHSF Press Release) .Sources Used:
SentryX News Updates | BR‐003 Packaging Design | EIC Accelerator Award | Hydrogel Drug Delivery Studies | PMC9468112 Study Disclosure
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.